Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group.

Authors :: Bastos‐Oreiro, M.
Abrisqueta, P.
Gutierrez, A.
Jimenez‐Ubieto, A.
Gonzalez de Villambrosia, S.
Córdoba, R.
López, A.
Poza, M.
Ceballos, E. Pérez
Navarro, B.
Muntañola, A.
Donato, E.
Escoda, L.
Luzardo, H.
Peñarrubia, M. J.
Pardal, E.
Belmonte, D. García
Lozada, C. Salazar
García‐Sancho, A. Martín
Source :: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p434-436, 3p
Publication Year :: 2023
Abstract: B Introduction: b Several new therapeutic agents have been introduced in recent years for the treatment of relapsed/refractory (r/r) aggressive B cell lymphoma (ABCL) (diffuse large B cell lymphoma [DLBCL] and high-grade B cell lymphomas [HGBCL]), such as new monoclonal antibodies (MA), bispecific antibodies (BA) and CAR-T cell therapy. From 354 patients that received >2 lines of treatment, 130 (37%) received CAR-T cell therapy, 69 (19%) pola-based, 5 (1%) TL, 55 (15%) BA, and 299 (84 %) did not receive NTs. Novel therapies for the treatment of relapsed-refractory aggressive B-cell lymphoma increase survival. [Extracted from the article]

Full Text Access

Tools